Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1611 1612 1628
This examiner grants 37% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19548797 | PDK1 REGULATORY COMPOUND AND COMPOSITION CONTAINING THE SAME | Non-Final OA | PROVIBIO CO., LTD. |
| 18353069 | Combination Therapeutics Comprising Nrf2 Agonists and Antivirals for Treating Viral Infections | Non-Final OA | The Regents of the University of California |
| 17420252 | PI4-Kinase Inhibitors with Anti-Cancer Activity | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18698401 | TRICYCLIC SULFAMIDES AND SULTAMS | Non-Final OA | Merck Sharp & Dohme LLC |
| 18872672 | COMPOSITIONS COMPRISING DISODIUM 5,10-METHYLENE-(6R)-TETRAHYDROFOLATE | Non-Final OA | MERCK PATENT GMBH |
| 18007433 | METHODS FOR REDUCING GLYCOSPHINGOLIPID CONCENTRATION IN BRAIN TISSUE AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES INVOLVING THE SAME | Final Rejection | GENZYME CORPORATION |
| 18277257 | LYSOSOME-ASSOCIATED MEMBRANE PROTEIN TARGETING COMPOUNDS AND USES THEREOF | Non-Final OA | RAMOT AT TEL-AVIV UNIVERSITY LTD. |
| 18245970 | COMBINATION COMPOSITIONS HAVING ANTI-VIRAL ACTIVITIES AND USES THEREOF | Non-Final OA | RAMOT AT TEL-AVIV UNIVERSITY LTD. |
| 18373418 | COMPOSITIONS AND METHODS FOR IMPROVING CARDIAC STRUCTURE AND/OR FUNCTION | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18251670 | CXCR1/CXCR2 INHIBITORS FOR USE IN TREATING MYELOFIBROSIS | Non-Final OA | Icahn School of Medicine at Mount Sinai |
| 17912802 | USE OF A COMPOUND OR COMPOSITION COMPRISING AN INHIBITOR OF NLRP1 INFLAMMASOME ACTIVATION FOR THE TREATMENT OF HUMAN AIRWAY INFLAMMATION | Final Rejection | Agency for Science, Technology and Research |
| 18329957 | METHODS OF TREATING DISEASES AND DISORDERS ASSOCIATED WITH CALCIUM ION SIGNALING | Final Rejection | Temple University-Of the Commonwealth System of Higher Education |
| 17877361 | ANTI-MICROBIAL SULFONAMIDE PHARMACEUTICAL COMPOSITIONS FOR EXTERNAL USE | Final Rejection | Rem Brands, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy